Celularity vs Scynexis
Celularity is the larger business, with $26.6m of revenue in fiscal 2025 against $20.6m for Scynexis (1.3 times as much). Scynexis grew faster (449.9% against -51.0%). Scynexis kept more of each dollar of sales as profit: a net margin of -41.8% against -345.4%.
| Latest fiscal year | CelularityCELU, 2025 | ScynexisSCYX, 2025 |
|---|---|---|
| Revenue | $26.6m | $20.6m |
| Revenue growth | -51.0% | 449.9% |
| Net income | −$91.7m | −$8.6m |
| Operating margin | -230.9% | -78.0% |
| Net margin | -345.4% | -41.8% |
| Return on equity | — | -16.5% |
| Free cash flow | −$13.3m | −$5.3m |
| Cash | $6.2m | $21.3m |
| Total debt | $33.8m | $0 |
| Debt to equity | — | 0.0% |
| Dividend per share | — | — |
| Dividend yield | — | — |
| Share buybacks | — | — |
| Employees | 115 | 18 |
| Market value | $24.0m | $39.1m |
| Price vs our value range | — | — |
| Moat score | 18 (Weak) | 9 (Weak) |
| Insider trades, 12 months | 0 buys, 0 sales | 1 buys, 0 sales |